Skip to main content
Smart Investors Daily
CF

NYSE · CFX

Colfax Corporation

Industrials · Industrial - Machinery

$39.06

Down-$1.53 (-3.77%)

Updated Sep 12, 2026, 4:08 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
2.12B
P/E ratio
-1.17
Dividend yield
0.00%
52-week range
— – —
Volume
2.95M
Avg. volume
871.93K

Price performance

CFX price history

1M range · 0 trading sessions · Daily adjusted prices

CFX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CFX news

The latest Smart Investors Daily articles mentioning CFX.

CFX research

Overview

Company profile and research snapshot.

Company profile

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$51.00
Implied upside
Analysts
CFX recent ratings
DateFirmRatingTarget
Mar 15, 2022KeybancOverweight
Mar 15, 2022Morgan StanleyEqual-Weight
Mar 2, 2022RBC CapitalSector Perform
Feb 23, 2022StifelBuy
Feb 8, 2022Seaport GlobalNeutral
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Apr 5, 2022

Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation

Wilmington, DE, April 05, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the “Separation”) of its fabrication technology business into an independent, publicly traded company, ESAB Corporation (“ESAB”) (NYSE: ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued and outstanding shares of Enovis common stock at a one-for-three ratio.

GlobeNewswire Inc. · Mar 28, 2022

Colfax Announces Board of Directors for Post-Spinoff ESAB

Wilmington, DE, March 28, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company which will renamed Enovis Corporation (“Enovis”) following the expected April 4, 2022 consummation of the Company’s previously announced spin-off of its fabrication technology business (the “Separation"), which will operate as ESAB Corporation (“ESAB”) after the Separation, today announced the future composition of the full ESAB Board of Directors (the “Board”).

Benzinga · Mar 15, 2022

KeyBanc, Morgan Stanley Slash Price Target On Colfax

Colfax Corp's (NYSE: CFX) price target has been lowered to $52 (an upside of 41%) from $60 by KeyBanc analyst Jeffrey Hammond, following ESAB/Enovis's 2022 Investor Day to reflect broadly lower peer multiples. The analyst maintained an Overweight rating on CFX shares. Related: Colfax's Q4 Earnings Morgan Stanley also lowered its price target on Colfax to $41 ...Full story available on Benzinga.com

GlobeNewswire Inc. · Mar 14, 2022

Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation

Wilmington DE,, March 14, 2022 (GLOBE NEWSWIRE) -- —Colfax Corporation (“Colfax”) (NYSE: CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of the outstanding common stock of ESAB Corporation (“ESAB”) to Colfax shareholders of record as of the close of business on March 22, 2022 (the “Record Date”), and (b) that the previously announced reverse stock split of all issued and outstanding shares of Colfax Common Stock will be effected at a one-for-three ratio (the “Reverse Stock Split”) following the distribution of the ESAB shares. The distribution is expected to be payable after the market close on April 4, 2022 (“Distribution Date”). As a result of the distribution, Colfax shareholders will receive one share of ESAB common stock for every three shares of Colfax common stock they hold on the Record Date (pre-Reverse Stock Split ratio). Immediately following the distribution, Colfax will retain 10% of the outstanding shares of ESAB common stock, which Colfax intends to divest within 12 months after the separation in a tax-efficient exchange for its outstanding debt.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.